Revvity, Inc. (NYSE:RVTY) Shares Bought by Siemens Fonds Invest GmbH

Siemens Fonds Invest GmbH lifted its holdings in shares of Revvity, Inc. (NYSE:RVTY - Free Report) by 264.8% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 13,357 shares of the company's stock after acquiring an additional 9,696 shares during the quarter. Siemens Fonds Invest GmbH's holdings in Revvity were worth $1,491,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in RVTY. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in Revvity in the 4th quarter valued at $16,293,000. Vermillion Wealth Management Inc. acquired a new position in Revvity in the 4th quarter valued at $41,000. Mackenzie Financial Corp raised its holdings in Revvity by 22.3% in the 4th quarter. Mackenzie Financial Corp now owns 14,381 shares of the company's stock valued at $1,605,000 after acquiring an additional 2,619 shares in the last quarter. Forum Financial Management LP raised its holdings in Revvity by 51.9% in the 4th quarter. Forum Financial Management LP now owns 3,545 shares of the company's stock valued at $396,000 after acquiring an additional 1,211 shares in the last quarter. Finally, Toronto Dominion Bank raised its holdings in Revvity by 40.7% in the 4th quarter. Toronto Dominion Bank now owns 58,374 shares of the company's stock valued at $6,515,000 after acquiring an additional 16,881 shares in the last quarter. 86.65% of the stock is currently owned by institutional investors.

Revvity Stock Down 1.6%

NYSE RVTY traded down $1.47 during mid-day trading on Friday, reaching $90.44. The stock had a trading volume of 2,068,378 shares, compared to its average volume of 952,837. Revvity, Inc. has a 1 year low of $88.01 and a 1 year high of $129.50. The stock has a market cap of $10.66 billion, a PE ratio of 40.92, a price-to-earnings-growth ratio of 3.82 and a beta of 1.02. The company has a fifty day moving average price of $95.02 and a 200 day moving average price of $108.10. The company has a debt-to-equity ratio of 0.41, a current ratio of 3.60 and a quick ratio of 3.03.

Revvity (NYSE:RVTY - Get Free Report) last announced its earnings results on Monday, April 28th. The company reported $1.01 earnings per share for the quarter, beating analysts' consensus estimates of $0.96 by $0.05. The business had revenue of $664.76 million during the quarter, compared to analyst estimates of $662.30 million. Revvity had a net margin of 9.81% and a return on equity of 7.68%. The company's quarterly revenue was up 2.3% compared to the same quarter last year. During the same period in the previous year, the business earned $0.98 EPS. On average, research analysts expect that Revvity, Inc. will post 4.94 earnings per share for the current year.

Revvity Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 8th. Stockholders of record on Friday, July 18th will be given a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a dividend yield of 0.31%. The ex-dividend date is Friday, July 18th. Revvity's dividend payout ratio is 11.91%.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on RVTY shares. UBS Group raised Revvity from a "neutral" rating to a "buy" rating and lowered their price target for the stock from $145.00 to $115.00 in a report on Thursday, May 1st. Barclays lowered their price target on Revvity from $140.00 to $110.00 and set an "overweight" rating for the company in a report on Thursday, April 10th. Wells Fargo & Company lowered their price target on Revvity from $130.00 to $102.00 and set an "equal weight" rating for the company in a report on Thursday, April 17th. Raymond James restated an "outperform" rating and set a $120.00 price objective (down previously from $145.00) on shares of Revvity in a research report on Tuesday, April 29th. Finally, Wall Street Zen lowered Revvity from a "buy" rating to a "hold" rating in a research report on Saturday, May 24th. Five equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $125.64.

Revvity Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.